Alnylam Pharmaceuticals Inc (MEX:ALNY)
MXN 5899.69 0 (0%) Market Cap: 699.59 Bil Enterprise Value: 669.88 Bil PE Ratio: 0 PB Ratio: 1,075.42 GF Score: 78/100

Alnylam Pharmaceuticals Inc to Discuss FDA Approval of OXLUMO (Lumasiran) Conference Call Transcript

Nov 24, 2020 / 01:00PM GMT
Release Date Price: MXN3100
Operator

Ladies and gentlemen, thank you for standing by. Welcome to Alnylam Pharmaceuticals Conference call to discuss our approval of OXLUMO. (Operator Instructions) Please be advised that this call is being taped at the company's request.

I'd now like to turn the call over to the company. Please go ahead.

Christine Regan Lindenboom
Alnylam Pharmaceuticals, Inc. - Senior VP of IR & Corporate Communications

Good morning. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today are John Maraganore, our Chief Executive Officer; Akshay Vaishnaw, our President of R&D; and Andy Orth, our Senior Vice President, Head of U.S. Business. Also joining us and available for Q&A are Yvonne Greenstreet, our President and Chief Operating Officer; and Pritesh Gandhi, General Manager of the Lumasiran program.

For those of you participating via conference call, the slides that is made available via webcast can also be accessed by going to the Investor page of our website,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot